HPV serum antibodies as predictors of survival and disease progression in patients with HPV-positive Squamous cell carcinoma of the Oropharynx

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2861-2869

  Dahlstrom, Kristina R ^a   Anderson, Karen S ^b   Cheng, Julia N ^b   Chowell, Diego ^b   Li, Guojun ^a   Posner, Marshall ^c   Sturgis, Erich M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALGRANULIN; E1 ANTIGEN; E2 ANTIGEN; E4 ANTIGEN; E5 ANTIGEN; E6 ANTIGEN; E7 ANTIGEN; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN G; L2 ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ANTIBODY; VIRUS DNA;

ADULT; ALCOHOL CONSUMPTION; AMINO TERMINAL SEQUENCE; ANTIBODY SPECIFICITY; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANALYSIS; HAZARD RATIO; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SMOKING; SQUAMOUS CELL CARCINOMA; AGED; BLOOD; CANCER GRADING; CARCINOMA, SQUAMOUS CELL; COMPLICATION; FOLLOW UP; GENETICS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROGNOSIS; RISK FACTOR;

AGED; ANTIBODIES, VIRAL; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84941961689     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3323     Document Type: Article

References (25)

1. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301.
2. Reuschenbach M, Waterboer T, Wallin KL, Einenkel J, Dillner J, Hamsikova E, et al. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-Associated cancers. Int J Cancer 2008;123:2626-31.
3. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: The International Agency for Research onCancer multicenter study. J Natl Cancer Inst 2003;95:1772-83.
4. Zumbach K, HoffmannM, Kahn T, Bosch F, Gottschlich S, Gorogh T, et al. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-And-neck squamous-cell carcinoma. Int J Cancer 2000;85:815-8.
5. MeschedeW, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, et al. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998;36:475-80.
6. Rosales R, Lopez-Contreras M, Cortes RR. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: Correlation with presence of papillomavirus DNA. J Med Virol 2001;65: 736-44.
7. Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, et al. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Arch Virol 2006;151:1899-916.
8. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125-31.
9. Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, et al. Human papillomavirus infections and upper aerodigestive tract cancers: The ARCAGE study. J Natl Cancer Inst 2013;105: 536-45.
10. Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013;31:2708-15.
11. Anderson KS. Multiplexed detection of antibodies using programmable bead arrays. Methods Mol Biol 2011;723:227-38.
12. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9.
13. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
14. Mehta V, Yu GP, Schantz SP. Population-based analysis of oral and oropharyngeal carcinoma: Changing trends of histopathologic differentiation, survival and patient demographics. Laryngoscope 2010;120: 2203-12.
15. Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142-8.
16. Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Ann Oncol 2011;22:1071-7.
17. Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014;32:3365-73.
18. Wong J, Sibani S, Lokko NN, LaBaer J, Anderson KS. Rapid detection of antibodies in sera using multiplexed self-Assembling bead arrays. J Immunol Methods 2009;350:171-82.
19. Anderson KS, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, et al. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer 2011;104:1896-905.
20. D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, et al. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol 2014;32:2408-15.
21. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999;9:423-30.
22. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
23. Porras C, Bennett C, Safaeian M, Coseo S, Rodriguez AC, Gonzalez P, et al. Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis 2010;10:238.
24. Holzinger D, Schmitt M, Dyckhoff G, Benner A, Pawlita M, Bosch FX. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res 2012;72:4993-5003.
25. Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 2002;102:152-8.